ASPAC III Acquisition Corp. (ASPC) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

Medium Risk
Moderate dilution risk
Last updated: May 08, 2026

Risk Assessment Details

Potential Dilution: 240.22% of current shares
Recent Dilution: 0% (2 years)
Historical Dilution Factor: minimal recent dilution
Outstanding Shares
2.3M
Potential Supply
5.6M
Additional shares possible
Splits
None
Past 2 years

Summary

ASPC currently has 2.34M outstanding shares. with significant dilution risk as 5.62M authorized shares could dilute existing holders by 240.2%. The company has not diluted shareholders through share issuances in the past 2 years, which is positive for existing holders.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
May 08, 2026

10-Q filing | 2.3M shares outstanding

2.3M 5.6M
Jan 23, 2026

8-K filing: A SPAC III Acquisition Corp. exchanged 1,499,900 Class B ordinary shares for 1,499,900 Class A ordinary shares with A SPAC III (Holdings) Corp.

2.3M 5.6M
Oct 27, 2025

8-K filing: A SPAC III (Holdings) Corp.'s Sponsor transferred 100,000 Class B ordinary shares to a third party in exchange for voting 621,084 Class A ordinary shares in favor of a proposal.

6M 5.6M
Aug 13, 2025

10-Q filing | 6.0M shares outstanding

6M 5.6M
May 27, 2025

8-K filing: A SPAC III Acquisition Corp. entered into a merger agreement with Bioserica International Limited, A SPAC III Mini Acquisition Corp., and A SPAC III Mini Sub Acquisition Corp., with Bioserica shareholders receiving consideration of $200,000,000 in stock, comprised of newly issued Class B Ordinary Shares of the Purchaser at a price of $10.00 per share, plus up to a maximum of 1,786,000 Purchaser Class A Ordinary Shares.

6M 5.6M
May 09, 2025

10-Q filing | 6.0M shares outstanding

6M 5.6M
Mar 05, 2025

10-K filing | 6.6M shares outstanding

6.6M 5.6M
Jan 27, 2025

8-K filing: A SPAC III Acquisition Corp. executed an agreement with Bioserica International Limited for a business combination, involving a reincorporation merger and an acquisition merger, with the aggregate consideration to be paid to Bioserica's shareholders being $200,000,000 in newly issued ordinary shares of the Purchaser at $10.00 per share. ($200.0M proceeds)

6.6M 5.6M
Dec 20, 2024

10-Q filing | 6.6M shares outstanding

6.6M 5.6M
Nov 22, 2024

8-K filing: A SPAC III Acquisition Corp. consummated an IPO of 5,500,000 units at $10.00 per unit, a private placement of 280,000 units to the Sponsor at $10.00 per unit, the issuance and sale of 500,000 Over-Allotment Option Units at $10.00 per unit, and a private placement of an additional 5,000 Private Placement Units to the Sponsor. ($62.85M proceeds)

N/A 5.6M
Nov 19, 2024

8-K filing: A SPAC III Acquisition Corp. consummated its IPO of 5,500,000 units at $10.00 per unit, generating gross proceeds of $55,000,000. ($55.0M proceeds)

N/A 5.6M
Nov 13, 2024

8-K filing: A SPAC III Acquisition Corp. consummated its IPO of 5,500,000 units at $10.00 per unit, generating gross proceeds of $55,000,000, and simultaneously completed a private placement with A SPAC III (Holdings) Corp. of 280,000 private units at $10.00 per unit, generating total proceeds of $2,800,000. ($57.8M proceeds)

N/A 5.6M
Nov 05, 2024

S-1/A filing: This is an S-1/A filing for an initial public offering of units by A SPAC III Acquisition Corp., a blank check company seeking a business combination in the ESG and material technology sector.

N/A 5.6M
Oct 25, 2024

S-1/A filing: A SPAC III Acquisition Corp. is offering 5,500,000 units at $10.00 per unit, each consisting of one Class A ordinary share and one right to receive one-tenth of one Class A ordinary share upon consummation of an initial business combination. The company is a blank check company seeking a business combination in the ESG and material technology sector.

N/A 5.6M
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime